CASE REPORT

Open Access

COVID-19 and emergencies in patients with diabetes: two case reports



Rajib Kumar Dey^{1*}, Abdullah Isneen Hilmy¹, Hisham Ahmed Imad^{2,3}, Abdul Azeez Yoosuf¹ and Ali Abdulla Lath eef^{1,4}

Abstract

Background: Maldives reported its first Coronavirus disease 2019 (COVID-19) case on March 7th, 2020. Since then more than 9400 positive cases and 33 deaths have been reported. Recently studies have shown that COVID-19 patients with diabetes had a poor prognosis and a higher mortality rate when compared to the non-diabetic patients. Poorly controlled diabetic patients had a higher incidence of complications like diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) which might have been precipitated by COVID-19. DKA and HHS are potentially lethal but preventable conditions. During this pandemic, although cases of uncontrolled diabetes are frequently reported, there is scarcity in reporting of cases with diabetic emergencies.

Case presentation: Case 1 was a 53-year old Asian male, admitted on Day 10th of illness with DKA with acute kidney injury, and Moderate COVID-19. Case 2 was a 72-year old Asian male, admitted with mild COVID-19 who developed HHS with acute kidney injury on day 9 of illness. Both patients were managed conservatively in intensive care unit, with intravenous fluids and insulin.

Conclusion: Clinicians should focus on close monitoring of diabetic patients with COVID-19, to prevent diabetic emergencies like DKA and HHS. It is important to aggressively manage these conditions for a favorable outcome.

Keywords: COVID-19, Diabetes, Diabetic ketoacidosis, Hyperosmolar hyperglycemic state, Diabetic emergencies, Pandemic

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in China in December 2019 [1]. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11th, 2020 [2] and since then there have been over thirty million confirmed cases and over nine hundred thousand deaths worldwide [3]. Maldives confirmed its first case of COVID-19 on March 7th, 2020 and till date, more than nine thousand four hundred cases and thirty-three deaths have been reported [4].

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/1.0/) apolies to the data made available in this article, unless otherwise stated in a credit line to the data.

from COVID-19 [5].

Studies have shown that elderly age and people of any age with certain medical conditions like diabetes mel-

litus, cardiovascular disease, cancer, obesity, chronic

obstructive pulmonary disease, and chronic kidney dis-

ease are at increased risk of severe disease and mortality

The prevalence of diabetes in 1590 Chinese patients

with COVID-19 was 8.2%. However, the prevalence

of diabetes increased to 34.6% in patients with severe

COVID-19 [6]. In a recent study done in New York City (USA) in patients with COVID-19, the prevalence of dia-

betes and obesity was higher in individuals admitted to hospital than those not admitted to hospital (34.7% vs 9.7% for diabetes and 39.5% vs 30.8% for obesity, respec-

tively) [7]. In Italy, it was reported that 35.5% of patients

^{*}Correspondence: dr_rajibdey@yahoo.co.uk

¹ Department of Internal Medicine, Indira Gandhi Memorial Hospital, Male', Maldives

who died from COVID-19 had diabetes, a prevalence greater than 3 times that of the general population [8].

A survey done in England (UK) showed that out of the 23 804 patients with COVID-19 who died in hospital, 32% had type 2 diabetes and 1.5% had type 1 diabetes, with 2.03 and 3.5 times the odds of dying compared with patients without type 2 diabetes and type 1 diabetes respectively [9]. The French CORONADO study revealed 3% had type 1 diabetes, 88.5% had type 2 diabetes, 5.4% had other type diabetes, and 3.1% were diagnosed at admission [10]. All these studies have shown that diabetic patients with COVID-19 had a worse prognosis and a higher mortality rate.

Diabetic emergencies like DKA and HHS are lifethreatening but preventable. These complications can be precipitated by any infectious disease including COVID-19. Here we describe two cases of critical COVID-19 complicated by DKA and HHS managed in the Maldives.

Case presentation

Case 1

A 53-year-old Asian male patient presented to the emergency department with a history of fever for 10 days with fatigue, myalgia, ageusia, hyposmia, and one episode of vomiting. The patient also complained of polydipsia, polyuria, and nocturia for 1 week with generalized weakness and mild breathlessness with non-productive cough for 2 days. He had a history of Hypertension and Diabetes mellitus but was not on medications. He was managing his blood glucose by lifestyle modification with diet and exercise.

Table 1 Laboratory investigations in case 1

On initial evaluation, the patient was dehydrated with a heart rate of 108 beats per minute, blood pressure of 126/76 mmHg, temperature of 36.8 °C, respiratory rate of 24 breaths per minute, and oxygen saturation of 91% in room air. His blood investigations showed plasma blood glucose of 1543 mg/dl, HbA1c 13.0%, blood urea 130 mg/dl, serum creatinine 2.9 mg/dl, serum sodium 145 mEq/L, serum potassium 5.3 mEq/L, and urine analysis was positive for ketones (Table 1). His arterial blood gas analysis (ABG) revealed compensated metabolic acidosis with high anion gap. Chest x-ray revealed bilateral airspace consolidations, more prominent on the left side involving almost all zones (Fig. 1). The patient was planned for ICU admission and as a part of routine COVID-19 testing in our hospital, rRT-PCR was done which was positive. Hence, he was shifted to our make-shift COVID hospital and admitted to the ICU.

The patient was started on empirical antibiotics, oxygen supplementation through nasal prongs, and DKA management was initiated mainly with cautious administration of intravenous fluids, insulin therapy, and potassium correction. All other possible communityacquired pathogens were excluded.

The patient's DKA and acute kidney injury (AKI) improved gradually which was evident by the normalization of renal function and serum sodium levels. He also developed thrombocytopenia during the course of treatment which improved over a week. The patient also showed improvement in his breathing as his oxygen saturation rose to 97% in room air and his repeat chest x-ray revealed resolution of consolidations. On

	25/07/2020	26/07/2020	27/07/2020	28/07/2020	29/07/2020	30/07/2020	02/08/2020
Hemoglobin, g/dl [range: 14–18]	14.7	12.8	13.4	12.0	12.3	12.3	12.7
Hematocrit, % [range: 40–54]	55.7	41.9	40.2	37	37.6	37.7	39
Leukocytes, 10 ³ /ml [range: 5.0–10.0]	7.20	9.16	8.12	7.18	5.78	3.92	6.56
Neutrophils % [range: 45–74]	73.9	81.5	77.9	74.5	80.9	53.6	50.7
Lymphocytes, % [range: 16–45]	19.6	15.9	19.4	23.6	14.6	35.3	40.3
Platelets, 10 ³ /ml [range: 150–450]	261	148	106	68.6	63.9	94.5	236
Urea, mg/dl [range: 19–44.1]	136.9	74.9	51.36	34.24	32.10	38.52	
Creatinine, mg/dl [range: 0.8–1.25]	2.9	1.4	1.19	0.90	0.78	0.83	
Na, mEq/L [range: 135–145]	149	164	159	149	139	139	
K, mEq/L [range: 3.5–5.1]	5.3	4.2	4.1	4.1	4.2	4.5	
AST, U/L [range: 05–34]	34	47	57	34	34	56	
ALT, U/L [range: 00–55]	19	28	33	30	28	43	
CRP, mg/ml [range: < 0.5]	17.6	19.8	9.71	14.10	17.90	14.29	4.03

HbA1c—13.0 %

Dengue Rapid: NS1 negative; Dengue IgM negative; Dengue IgG positive

SARS-CoV-2 rRT-PCR positive

Na: Sodium, K: Potassium, AST: Aspartate Transaminase, ALT: Alanine Transaminase, CRP: c-reactive protein, HbA1c: Glycosylated hemoglobin, NS1: nonstructural protein 1, SARS-CoV-2 rRT-PCR: severe acute respiratory syndrome Coronavirus 2 recombinant reverse transcriptase polymerase chain reaction



Fig. 1 X-ray of case 1 showing bilateral airspace consolidations more prominent on the left side involving almost all zones

the 7th day of admission, he was shifted out of ICU to the general ward in stable condition.

Case 2

A 78-year-old Asian male was brought to our makeshift COVID-19 hospital after being tested positive for rRT-PCR. The patient had a history of diabetes mellitus, hypertension, and recurrent ischemic stroke. He was on regular medications which included antiplatelets, statins, losartan, and oral hypoglycemic agents. On admission, the patient had a mild fever and dry cough for 2 days, and his examination revealed a pulse rate of 70 beats per

Table 2	Laboratory	/ investigatio	ns in case 2

minute, blood pressure of 150/70 mmHg, temperature of 37 °C, SaO_2 of 96% in room air, and respiratory rate of 20 per minute. His blood glucose was 90 mg/dl and HbA1c 6.6%. On the 9th day of admission, the patient gradually became drowsy and less responsive to general commands. On examination, his GCS was 10/15, pulse rate of 124 beats per minute, blood pressure of 180/100 mmHg, respiratory rate of 26 per minute, and oxygen saturation of 95% at room air. On chest auscultation, there was wheeze bilaterally present and crepitations on right infrascapular area.

His blood investigation showed a blood glucose level of 626 mg/dl, blood urea 64 mg/dl, serum creatinine 1.77 mg/dl, serum sodium 167 mEq/L, serum potassium 4.2 mEq/L, serum osmolality 378 mOsm/kg, urine analysis was negative for ketones (Table 2) and his arterial blood gas (ABG) analysis showed compensated metabolic acidosis. Chest x-ray revealed features of bilateral ill-defined airspace consolidations involving mostly lower zones with peripheral distribution (Fig. 2). Hence patient was shifted to ICU with the diagnosis of HHS with AKI and management was initiated with careful fluid administration, insulin therapy, and empirical antibiotics. All other possible co-infections were excluded. The patient gradually improved over a period of 1 week and was shifted out of ICU in stable condition.

Discussion

We have described two cases of diabetic emergencies precipitated by COVID-19. The first case was admitted with DKA complicated by pneumonia who recovered well. The second case was admitted with HHS complicated by bilateral pneumonia who had a delayed recovery.

Hemoglobin g/dl [range: 14–18]	11.3	11.4	10.5	9.1	11	9.2
Hematocrit, % [range: 40–54]	34	30	33	28	34.2	27
Leukocytes, 10 ³ /ml [range: 5.0–10.0]	8.37	7.71	14.7	15.5	11.2	11.0
Neutrophils, % [range: 45–74]	70.1	63.4	91.7	93	82.2	80
Lymphocytes, % [range: 16–45]	16.0	21.9	3.9	4.7	13.2	11.1
Platelets, 10 ³ /ml [range: 150–450]	174	180	240	179	180	176
Urea, mg/dl [range: 19–44.1]	59.9	44.9	64.2	59.9	29.96	
Creatinine, mg/dl [range: 0.8–1.25]	1.48	1.22	1.77	1.28	0.69	
Na, mEq/L [range: 135–145]	133	133	167	148	140	138
K, mEq/L [range: 3.5–5.1]	4.8	4.4	4.2	4.7	4.5	3.5
AST, U/I [range: 05–34]	23	26	22			
ALT, U/I [range: 00–55]	15	17	21			
CRP, mg/ml [range: < 0.5]	0.37	0.68	5.94	1.08	1.94	0.37

HbA1c-6.6 %

SARS-CoV-2 rRT-PCR positive

Na: Sodium, K: Potassium, AST: Aspartate Transaminase, ALT: Alanine Transaminase, CRP: c-reactive protein, HbA1c: Glycosylated hemoglobin, SARS-CoV-2 rRT-PCR: severe acute respiratory syndrome Coronavirus 2 recombinant reverse transcriptase polymerase chain reaction



Fig. 2 X-ray of case 2 showing bilateral ill-defined airspace consolidations involving mostly lower zones with peripheral distribution

To our knowledge, this is the first case report of COVID-19 with DKA, and HHS in the Maldives.

Older age and male sex have been associated with increased severity of COVID-19. In a study done in China, the overall case-fatality was 2.3% but it increased to 14.8% in individuals aged 80 years and older [11]. The prevalence of diabetes increases with age and hence the average age of COVID-19 patients with diabetes is older than the non-diabetic ones. Another study done on patients with COVID-19 with and without diabetes reported that the survivors were younger than the non-survivors and an age of 70 years and older was an independent risk factor for in-hospital death [12].

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds with angiotensin-converting enzyme 2 (ACE2) receptors which are highly expressed in pancreatic beta cells, lungs, kidneys, and small intestines [13]. ACE2 is the main enzyme in the renin-angiotensinaldosterone system (RAAS) system that catalyzes the conversion of angiotensin II to angiotensin I. It is possible that the entry of SARS-CoV-2 into the pancreatic islet cells may cause direct injury to the beta cells leading to insulin deficiency [14]. The viral entry may also cause the downregulation of ACE2 enzyme which may lead to unopposed angiotensin II, which further impedes insulin secretion [15]. Angiotensin II stimulates aldosterone secretion which leads to increased risk of hypokalemia. Therefore, it be necessary for a higher potassium supplementation in order to continue intravenous insulin to suppress ketogenesis [15].

A high glucose concentration has been shown to be an independent predictor of death and morbidity in COVID-19 [16]. Diabetic emergencies occur due to insulin deficiency aggravated by hyperglycemia, dehydration and acidosis-producing derangements in intermediary metabolism. The most common causes are underlying infection, disruption of insulin treatment and new onset of diabetes. In both our cases the aggravating factor was noted to be COVID-19.

In case 1, the patient presented on the 10th day of illness when he was diagnosed with DKA with pneumonia and in case 2, the patient was initially admitted with mild symptoms of COVID-19 but developed HHS with bilateral pneumonia on the 9th day of illness. Both the patients were managed in the ICU. Conservative intravenous fluid was administered by using boluses instead of a continuous drip. After every bolus, clinical markers of perfusion like mean arterial pressure, urine output measurement, capillary refill time (CRT), heart rate and lactate levels were monitored. And as patients with COVID-19 are more prone to develop pulmonary edema [17], patient's respiratory rate was monitored closely and chest auscultation was done at regular intervals in between fluid boluses [18].

Hyperglycemia in both patients were initially managed with Intravenous insulin infusion which was adjusted according to hourly blood glucose levels and was later changed to subcutaneous therapy. Serum electrolytes were closely monitored. Both patients had developed acute kidney injury along with the hyperglycemic crisis which gradually resolved within three days following fluid repletion. Empirical antibiotics were used in both the patients along with supplemental oxygenation via nasal prongs. Both the patients recovered over a period of 1 week.

Conclusion

It is important for physicians to be vigilant in diabetic patients admitted with COVID-19 as they are at increased risk of developing complications. Diabetic emergencies like DKA and HHS can be precipitated by COVID-19 infection, and if not recognized early and treated promptly, it may lead to catastrophic outcomes. Clinicians should focus on close monitoring of diabetic patients with COVID-19, to prevent diabetic emergencies like diabetic ketoacidosis and hyperosmolar hyperglycemic state. As diabetes and COVID-19 are both highly prevalent in the Maldives, a high degree of suspicion is required to diagnose diabetic ketoacidosis and hyperosmolar hyperglycemic state timely for a better prognosis. In patients who develop diabetic emergencies, the intravenous fluid should be used judiciously with

careful attention to markers of perfusion, to prevent volume overload and pulmonary edema.

Acknowledgements

We would like to express our gratitude to all the frontline workers across the globe for their bravery and dedication in combating this pandemic. In addition, we would like to thank everyone at the multiagency-taskforce overseeing the management of the current epidemic outbreak in the Maldives.

Authors' contributions

RKD: Conceptualization, writing-original draft, data collection. AIH: Writingreview and editing, data collection. HAI: Writing-review and editing. AAY: Review and validation. AAL: Supervision, review and validation. All authors read and approved the final manuscript.

Funding

There was no financial support for this clinical case report.

Availability of supporting data

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Internal Medicine, Indira Gandhi Memorial Hospital, Male', Maldives. ² Mahidol-Osaka Center for Infectious Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. ³ Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. ⁴ Technical Advisory Group, Health Emergency Operation Center, Male', Maldives.

Received: 15 October 2020 Accepted: 28 December 2020 Published online: 02 February 2021

References

- Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020. https://doi. org/10.1001/jama.2020.1097.publishedonlineJan30.
- Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Bio-Med. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397.
- Worldmeter: COVID-19 Coronavirus outbreak; https://www.worldomete rs.info/. Accessed 29 July 2020.
- 4. MoH. First case of COVID-19 confirmed in the Maldives.

- Certain Medical Conditions and Risk for Severe COVID-19 Illness. (n.d.). https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/ people-with-medical-conditions.html. Acessed 29 July 2020.
- Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. https://doi.org/10.1183/13993003.00547-2020.
- Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. https://doi.org/10.1136/bmj.m1966.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. https://doi. org/10.1001/jama.2020.4683.
- Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, Knighton P, Holman N, Khunti K, Sattar N, Wareham NJ. Type 1 and type 2 diabetes and COVID-19 related mortality in England: a whole population study (5/17/2020). SSRN: https://ssrn.com/abstract=3605225 or https://doi. org/10.2139/ssrn.3605225.
- Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500–15. https://doi.org/10.1007/s0012 5-020-05180-x.
- Epidemiology Working Group for NCIP Epidemic Response. Chinese Center for Disease Control and Prevention. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–51. https://doi.org/10.3760/cmaj.i ssn.0254-6450.2020.02.003.
- Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a twocenter, retrospective study. Diabetes Care. 2020;43(7):1382–91. https:// doi.org/10.2337/dc20-0598.
- Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020. https:// doi.org/10.1038/s41574-020-0353-9.Advanceonlinepublication.
- 14. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193–9. https://doi.org/10.1007/s00592-009-0109-4.
- Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127–33.
- Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020. https://doi. org/10.1016/j.jaci.2020.04.006.
- Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harris E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936.
- Bose S, Adapa S, Aeddula NR, Roy S, Nandikanti D, Vupadhyayula PM, Naramal S, Gayam V, Muppidi V, Konala VM. Medical management of COVID-19: evidence and experience. J Clin Med Res. 2020;12(6):329–43. https://doi.org/10.14740/jocmr4201.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

